TASCOM Co.,Ltd. (XKON:336040)

Market Cap	23.39B +25.5%
Revenue (ttm)	5.53B +85.0%
Net Income	-1.74B
EPS	-824.00
Shares Out	5.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	41
Open	4,095.00
Previous Close	4,100.00
Day's Range	4,095.00 - 4,095.00
52-Week Range	2,400.00 - 5,280.00
Beta	0.41
RSI	54.82
Earnings Date	n/a

About TASCOM

TASCOM Co.,Ltd. engages in the research and development, manufacturing, and sales of in vitro diagnostic medical devices. The company offers SimplexTAS, an in vitro diagnostic medical device for point-of-care diagnosis that can diagnose and monitor various diseases, such as diabetes, hyperlipidemia, liver disease, kidney disease, and infections. It also provides pen needles and syringes. The company was formerly known as YIDOBIO Inc. and changed its name to TASCOM Co.,Ltd. in September 2021. TASCOM Co.,Ltd. was founded in 2014 and is headquarte...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2014
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 336040

Financial Performance

In 2018, TASCOM's revenue was 5.53 billion, an increase of 84.97% compared to the previous year's 2.99 billion. Losses were -1.74 billion, 35.2% more than in 2017.